Mesenchymal Stem Cells with NF-kB Inducible Cytokine Secretion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively sense and respond to inflammatory environments by secreting physiological levels of anti-inflammatory cytokines, leading to potential side effects from excess cytokine secretion and inadequate inflammation regulation.
Innovation Solution
Development of nucleic acids with an NFκB inflammation response element linked to nucleotide sequences encoding anti-inflammatory cytokines like IL-4, IL-6, IL-10, and IL-13, integrated into mesenchymal stem cells (MSCs) to induce controlled secretion of these cytokines in response to inflammatory signals, minimizing side effects by turning off secretion when inflammation resolves.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-inflammatory cytokines are secreted continuously to treat chronic inflammation, then inflammation regulation is improved, but side effects from excess cytokine secretion increase
Solution Approach 1:
The patent applies dynamics by transitioning from continuous cytokine secretion to inducible secretion controlled by the NF-κB response element. The system dynamically adjusts cytokine production levels based on inflammatory signals, secreting cytokines only when inflammation is detected and stopping when inflammation resolves, thereby maintaining effective inflammation regulation while avoiding harmful effects from excessive cytokine secretion.
Solution Approach 2:
The patent implements feedback control through the NF-κB response element that senses inflammatory cytokine levels and regulates anti-inflammatory cytokine secretion accordingly. When inflammatory signals are detected, NF-κB is activated and induces cytokine secretion; when inflammation subsides, the signal ceases and secretion stops, creating a self-regulating system that prevents both under-treatment and over-treatment.
2Reliability
If constitutive expression of anti-inflammatory cytokines is used, then inflammation treatment effectiveness is improved, but physiological levels of cytokine secretion are not maintained
Solution Approach 1:
The patent replaces constitutive expression with dynamic, inducible expression controlled by the NF-κB response element. This allows the system to maintain physiological cytokine levels during normal conditions while enabling significant cytokine production only when inflammatory signals activate NF-κB, thereby achieving both effective inflammation treatment and maintenance of physiological homeostasis.
3Adaptability or versatility
If NF-κB response element is linked to anti-inflammatory cytokine gene, then controlled secretion in response to inflammation is achieved, but system complexity increases
Solution Approach 1:
The patent applies self-service by designing a system where the NF-κB response element automatically senses inflammatory conditions and regulates cytokine gene expression without external intervention. The system uses the body's own inflammatory signals to control its activity, eliminating the need for complex external control mechanisms while achieving precise, context-appropriate cytokine secretion.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for targeted and reversible secretion of anti-inflammatory cytokines, effectively modulating macrophage polarization and reducing chronic inflammation while minimizing adverse effects, enhancing tissue regeneration and therapeutic efficiency.
Implementation Method 1
an NFκB inflammation response element operably linked to a nucleotide sequence encoding an anti-inflammatory cytokine
Data Source
AI summary
Provided are compositions and methods for production of anti-inflammatory cytokines, growth factors, or chemokines. Provided are nucleic acids (e.g., expression vectors) that include an NFκB inflammation response element operably linked to a nucleotide sequence encoding an anti-inflammatory cytokine (e.g., IL-4). In some cases, the nucleic acid is an expression vector selected from: a linear expression vector, a circular expression vector, a plasmid, and a viral expression vector. Also provided are cells (e.g., mesenchymal stem cells—MSCs) comprising a nucleic acid that includes an NFκB inflammation response element operably linked to a nucleotide sequence encoding an anti-inflammatory cytokine. In some cases, the nucleic acid is integrated into the cell's genome. Also provided are methods for treating an individual having an inflammation-associated ailment, which can include administering an MSC to the individual, where the MSC includes an NFκB inflammation response element operably linked to a nucleotide sequence encoding an anti-inflammatory cytokine.